文献速递分子诊断临床微生物

Cobas Liat CT/NG/MG 核酸检测在临床实验室及即时检测场景中的敏感性与特异性

Sensitivity and specificity of the Cobas Liat CT/NG/MG nucleic acid test in a clinical laboratory setting and point-of-care location.
PubMed 文献 · J Clin Microbiol · 2025-10-29

本研究为多中心非干预研究,在美国13个即时检测(POC)站点纳入4800名可评估参与者,以三种FDA批准NAAT和一种实验室自建方法组成的复合参考标准,评估Cobas Liat CT/NG/MG检测的性能。结果显示各分析物特异性均>97%,除女性尿液外敏感性≥92%,性能不受症状状态影响,且培训与未培训用户间无显著差异。

要点

  • Cobas Liat CT/NG/MG检测在POC场景中各分析物特异性>97%,除女性尿液外敏感性≥92%。
  • 检测性能不受症状状态影响,培训与未培训用户间无统计学显著差异。
  • 检测周转时间约20分钟,在POC可达到中心实验室的准确性。

核心结论

  • Cobas Liat CT/NG/MG检测在POC场景中对CT/NG/MG检测表现出良好的临床性能,具有高敏感性和特异性,且不受症状状态影响。

研究设计与样本

  • 非干预性多中心研究,从美国13个地理分布的POC站点招募有症状/无症状参与者,纳入4800名可评估者。
  • 采用临床医生采集和自采集的尿液/阴道拭子标本,以三种FDA批准NAAT和一种实验室自建检测组成的复合参考标准(CRS)确定敏感性及特异性。

主要发现

  • 在4800名可评估参与者中,40.4%(n=1941)有症状,51.9%(n=2489)出生时为女性。
  • Cobas Liat CT/NG/MG检测各分析物特异性均>97%,除女性尿液外敏感性≥92%。
  • 女性尿液敏感性:CT≥87%,NG≥83%,MG≥77%。
  • 培训与未培训用户间的性能结果无统计学显著差异。

临床怎么用

  • POC检测可促进快速病原体鉴定和准确治疗,从而减少对经验性治疗的依赖。
  • 检测周转时间约20分钟,在POC即可获得中心实验室水平的准确性,适用于临床医生采集和自采集样本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sexually transmitted infections, e.g., Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Mycoplasma genitalium (MG), present with similar signs/symptoms and are often treated empirically due to delays in receiving diagnostic test results. This study evaluated the clinical performance of the Cobas Liat CT/NG/MG nucleic acid amplification test (NAAT) in detecting these pathogens in a point-of-care (POC) setting. This non-interventional, multicenter study recruited symptomatic/asymptomatic participants from 13 geographically diverse POC sites across the USA. Prospective clinician- and self-collected specimens (urine/vaginal swabs) were used to determine the sensitivity and specificity of the Cobas Liat CT/NG/MG test relative to the composite reference standard (CRS), determined using a combination of results from three FDA-approved NAATs and one laboratory-developed test. Among 4,800 evaluable participants, 40.4% (n = 1,941) were symptomatic, and 51.9% (n = 2,489) were female at birth. The Cobas Liat CT/NG/MG test demonstrated good clinical performance across all specimen types regardless of symptom status, with specificity >97% for each analyte, and sensitivity ≥92%, except female urine (≥CT 87%, NG ≥ 83%, MG ≥ 77%). The test was considered easy to use, and no statistically significant difference in performance results was observed between trained/untrained users. The Cobas Liat CT/NG/MG test demonstrated good clinical performance, with high sensitivity and specificity for CT/NG/MG detection, regardless of symptom status. The assay provides a short turn-around time (approximately 20 min) with centralized testing laboratory accuracy at the POC for self- and clinician-collected samples. POC testing can facilitate rapid pathogen identification and accurate treatment, thereby mitigating the need for empiric treatment.IMPORTANCENucleic acid amplification tests are the preferred method for diagnosing CT and NG infections and are the only reliable tests for MG; however, delays in receiving results can lead to empiric treatment, potentially causing misdiagnosis and overtreatment of STIs. Point-of-care testing could mitigate these issues by enabling rapid pathogen identification and treatment, but no rapid POC tests are currently available for the detection of CT, NG, and MG despite the similarity of symptoms, and these three pathogens being responsible for the majority of symptomatic STIs in some settings. Our findings suggest that the Cobas Liat CT/NG/MG assay may help to reduce reliance on empiric treatment of symptoms and minimize resulting return visits for unresolved infections. Use of the Cobas Liat CT/NG/MG assay may also result in improved patient outcomes, help realize population benefits by reducing the duration of infection and potentially transmission, and reduce healthcare costs.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Van Der Pol B, Arcenas R, Boraas C, et al. Sensitivity and specificity of the Cobas Liat CT/NG/MG nucleic acid test in a clinical laboratory setting and point-of-care location. J Clin Microbiol. 2025. PMID: 41159798. doi:10.1128/jcm.00706-25

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。